French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC)

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 4, 2006, Pages 983-994

  Bensadoun, René Jean ^a   Bénézery, Karen ^a   Dassonville, Olivier ^a   Magné, Nicolas ^a   Poissonnet, Gilles ^a   Ramaïoli, Alain ^a   Lemanski, Claire ^c   Bourdin, Sylvain ^d   Tortochaux, Jacques ^e   Peyrade, Frédéric ^a   Marcy, Pierre Yves ^a   Chamorey, Emmanuel ^a   Vallicioni, Jacques ^a   Seng, Hang ^f   Alzieu, Claude ^g   Géry, Bernard ^h   Chauvel, Pierre ^a   Schneider, Maurice ^a   Santini, José ^b   Demard, François ^a   Calais, Gilles ⁱ   more..

^a CENTRE ANTOINE LACASSAGNE   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c CENTRE VAL D AURELLE   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e CENTRE JEAN PERRIN   (France)

^f CENTRE HENRI BECQUEREL   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h CENTRE FRANÇOIS BACLESSE   (France)

ⁱ CHU BRETONNEAU   (France)

Author keywords

Chemoradiation; Hypopharynx carcinoma; Oropharynx carcinoma; Phase III prospective clinical trial; Twice daily radiotherapy

Indexed keywords

CHEMORADIATION; HYPOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; PHASE III PROSPECTIVE CLINICAL TRIAL; TWICE-DAILY RADIOTHERAPY;

BIOMEDICAL ENGINEERING; CHEMOTHERAPY; ONCOLOGY; RADIATION EFFECTS; TUMORS;

RADIOTHERAPY;

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG INFUSION; DYSPHAGIA; ENTERIC FEEDING; ERYTHEMA; FEMALE; FRANCE; GASTROSTOMY; HUMAN; HYPOACUSIS; HYPOPHARYNX; HYPOPHARYNX CANCER; LARYNX EDEMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OROPHARYNX; OROPHARYNX CANCER; PHARYNX CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SCLEROSIS; SKIN INFLAMMATION; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TRISMUS; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; FRANCE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; PHARYNGEAL NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33644524067     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.09.041     Document Type: Article

References (50)

1. E.E. Vokes, R.R. Weichselbaum, S.M. Lippman, W.K. Hong Head and neck cancer N Engl J Med 328 1993 184 194
2. J.C. Horiot, R. Le Fur, T. NGuyen Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy Radiother Oncol 25 1992 231 241
3. D.M. Brizel, M.E. Albers, S.R. Fisher Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer N Engl J Med 18 1998 1798 1804
4. V. Budach, M. Stuschke, W. Budach Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer Final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial J Clin Oncol 23 2005 1125 1135
5. G. Calais, M. Alfonsi, E. Bardet Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma J Natl Cancer Inst 91 1999 2081 2086
6. T. Hehr, J. Classen, U. Schreck Hyperfractionated accelerated radiotherapy alone and with concomitant chemotherapy to the head and neck Treated within and outside of randomized clinical trials Int J Radiat Oncol Biol Phys 58 2004 1424 1430
7. J.P. Pignon, J. Bourhis, C. Domenge, L. Designé Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma Three meta-analyses of updated individual data Lancet 355 2000 949 955
8. R.J. Bensadoun, M.C. Etienne, O. Dassonville Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx Clinical and pharmacological data of a French multicenter phase II study Int J Radiat Oncol Biol Phys 42 1998 237 245
9. J. Bourhis, A. Etessami, P. Wibault Altered fractionation radiotherapy in the management of head and neck carcinomas Advantages and limitations Curr Opin Oncol 16 2004 215 219
10. M. Al-Sarraf Cisplatin combinations in the treatment of head and neck cancer J Clin Oncol 21 1994 28 34
11. R.J. Bensadoun, J.C. Franquin, G. Ciais Low-energy He/Ne laser in the prevention of radiation-induced mucositis A multicenter phase III randomized study in patients with head and neck cancer Support Care Cancer 7 1999 244 252
12. D. Cowen, C. Tardieu, M. Schubert Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant Results of a double blind randomized trial Int J Radiat Oncol Biol Phys 38 1997 697 703
13. K.K. Fu, T.F. Pajak, A. Trotti Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas First report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16
14. L.H. Pinto, P.C. Canary, C.M. Araujo Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in Stages III and IV oropharyngeal carcinoma Int J Radiat Oncol Biol Phys 21 1991 557 562
15. A.S. Allal, D. Taussy, N. Mach Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience Int J Radiat Oncol Biol Phys 58 2004 1431 1436
16. J.T. Parsons, W.M. Mendenhall, S.P. Stringer Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck The University of Florida experience Head Neck 15 1993 87 96
17. A.S. Garden, W.H. Morrison, K.K. Ang Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck A comparison of two fractionation schedules Int J Radiat Oncol Biol Phys 31 1995 493 502
18. G.O. Griffiths, M.K. Parmar, A.J. Bailey A prospective quality of life in the CHART randomized trial in head and neck cancer Short-term and long-term patient reported symptoms. CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy Br J Cancer 81 1999 1196 1205
19. E. Hammerlid, L.O. Persson, M. Sullivan Quality of life effects of psychosocial intervention in patients with head and neck cancer Otolaryngol Head Neck Surg 120 1999 507 516
20. I. Dimery, W. Hong Overview of combined modality therapies for head and neck cancer J Natl Cancer Inst 85 1993 95 111
21. A. Garden Is there still a role for induction chemotherapy for head and neck cancer? J Clin Oncol 23 2005 1059 1060
22. M. Rooney, J. Kish, J. Jacobs Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120 hour 5FU infusion and Cisplatin Cancer 55 1985 1123 1128
23. A. Thyss, M. Schneider, J. Santini Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck Br J Cancer 54 1986 755 760
24. E.E. Vokes, R.L. Schilsky, R.R. Weichselbaum Induction chemotherapy with cisplatin, fluorouracil, and high dose leucovorin for locally advanced head and neck cancer A clinical and pharmacologic analysis J Clin Oncol 8 1990 241 247
25. T.C. Lo, A.L. Wiley Jr., F.J. Ansfield Combined radiotherapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx A randomized study Am J Roentgenol 126 1976 229 235
26. B. Jeremic, Y. Shibamoto, B. Milicic Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck A prospective randomized trial J Clin Oncol 18 2000 1458 1464
27. D.J. Adelstein, L.A. Kalish, G.L. Adams Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer An Eastern Cooperative Oncology Group Pilot Study J Clin Oncol 11 1993 2136 2142
28. J.P. Pignon, B. Baujat, J. Bourhis Apport des méta-analyses sur données individuelles au traitement des cancers ORL Cancer Radiothérapie 9 2005 31 36
29. A.A. Abitbol, K.S. Sridhar, A.A. Lewin Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-c (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma Cancer 80 1997 266 276
30. J.W. Denham, R.L. Abbot Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer Dose-limiting mucosal toxicity J Clin Oncol 9 1991 458 463
31. T.G. Wendt, G.G. Grabenbauer, C.M. Rödel Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer A randomized multicenter study J Clin Oncol 16 1998 1318 1324
32. R.J. Bensadoun, N. Magné, P.Y. Marcy, F. Demard Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients New trends in pathophysiology, prevention and treatment Eur Arch Otorhinolaryngol 258 2001 481 487
33. N. Magné, P.Y. Marcy, C. Foa Comparison between nasogastric tube feeding and percutaneous fluoroscopic gastrostomy in advanced head and neck cancer patients Eur Arch Otorhinolaryngol 258 2001 89 92
34. A.M. Allen, F. Worden, L.A. Dawson Feeding tube placement facilitates aggressive hyperfractionated chemoradiation (HXCRT) for unresectable head and neck cancer Int J Radiat Oncol Biol Phys 601 2004 S510 S511
35. R. Kallman The importance of schedule and drug dose intensity in combinations of modalities Int J Radiat Oncol Biol Phys 28 1994 761 771
36. M. Schneider, M.C. Etienne, G. Milano Phase II trial of cisplatin, fluorouracil, and pure l folinic acid for locally advanced head and neck cancer A pharmacokinetic and clinical survey J Clin Oncol 13 1995 1656 1662
37. M.S. Chambers, A.S. Garden, D. Rosenthal Intensity-modulated radiotherapy Is xerostomia still prevalent? Curr Oncol Rep 7 2005 131 136
38. N. Magné, P.Y. Marcy, E. Chamorey Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients A long-term quality of life analysis Head Neck 23 2001 678 682
39. P.D. Maguire, M.B. Meyerson, C.R. Neal Toxic cure Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community Int J Radiat Oncol Biol Phys 58 2004 698 704
40. D.M. Brizel, R.G. Prosnotz, S. Hunter Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer Int J Radiat Oncol Biol Phys 58 2004 1418 1423
41. M.S. Chambers, A.S. Garden, M.S. Kies, J.W. Martin Radiation-induced xerostomia in patients with head and neck cancer Pathogenesis, impact on quality of life, and management Head Neck 26 2004 796 807
42. H.K. Oh, M.S. Chambers, A.S. Garden Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients J Oral Maxillofac Surg 62 2004 139 144
43. F. Denis, P. Garaud, E. Bardet Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems Int J Radiat Oncol Biol Phys 55 2003 93 98
44. A.S. Garden, J.A. Asper, W.H. Morrison Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer 100 2004 1171 1178
45. U. Selek, A.S. Garden, W.H. Morrison Radiation therapy for early-stage carcinoma of the oropharynx Int J Radiat Oncol Biol Phys 59 2004 743 751
46. O. Dassonville, J.L. Formento, M. Francoual Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873 1878
47. N. Magné, X. Pivot, R.J. Bensadoun Radiochemotherapy of unresectable pharyngeal cancer Prognostic impact of the epidermal growth factor receptor levels Eur J Cancer 37 2001 2169 2177
48. D.M. Shin, N.J. Donato, R. Perez-Soler Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin Cancer Res 7 2001 1204 1213
49. D. Soulieres, N.N. Senzer, E.E. Vokes Multicentric phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 2004 77 85
50. N. Magné, J.L. Fischel, A. Dubreuil Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer Br J Cancer 86 2002 819 827